Development of a novel treatment strategy that targets erythropoietin receptors and HIF

我们的目的是确定重组人促红细胞生成素（EPO）和稳定缺氧诱导因子（HIF）的脯氨酰羟化酶（PHD）抑制剂治疗心力衰竭的新策略是否有用。EPO通过维持左心室收缩功能，提高小鼠生存期来保护压力过载诱导的左心室肥厚。至少在本研究中使用的剂量和治疗期间，PHD抑制剂未能显示出这样的保护作用。需要进一步的调查来解决这个问题。

Our objective was to determine whether novel strategies to treat heart failure with recombinant human erythropoietin (EPO) and a prolyl hydroxylase (PHD) inhibitor that stabilizes hypoxia-inducible factor (HIF) are useful. EPO protected the pressure-overload induced hypertrophied left ventricle in mice by maintaining left ventricular systolic function and improved the survival. The PHD inhibitor failed to demonstrate such a protective effect at least with the doses and treatment period usedin the present study. Further investigations are required to address the issue.